[go: up one dir, main page]

AU2206699A - Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions - Google Patents

Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions

Info

Publication number
AU2206699A
AU2206699A AU22066/99A AU2206699A AU2206699A AU 2206699 A AU2206699 A AU 2206699A AU 22066/99 A AU22066/99 A AU 22066/99A AU 2206699 A AU2206699 A AU 2206699A AU 2206699 A AU2206699 A AU 2206699A
Authority
AU
Australia
Prior art keywords
myopia
conditions
various
treat glaucoma
muscarinic agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU22066/99A
Inventor
Hwang-Hsing Chen
Andrew Hoffman
Abdelmoula Namil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Publication of AU2206699A publication Critical patent/AU2206699A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU22066/99A 1997-12-23 1998-12-22 Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions Abandoned AU2206699A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6862897P 1997-12-23 1997-12-23
US60068628 1997-12-23
PCT/US1998/027588 WO1999032489A1 (en) 1997-12-23 1998-12-22 Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions

Publications (1)

Publication Number Publication Date
AU2206699A true AU2206699A (en) 1999-07-12

Family

ID=22083746

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22066/99A Abandoned AU2206699A (en) 1997-12-23 1998-12-22 Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions

Country Status (2)

Country Link
AU (1) AU2206699A (en)
WO (1) WO1999032489A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9902374A3 (en) * 1999-07-15 2002-11-28 Sanofi Aventis Process for producing spiro[(4-cyclohexanone)-[3h]indol-2'[1'h]-on derivatives and intermediates
MXPA04010552A (en) * 2002-04-26 2005-01-25 Schering Corp Muscarinic antagonists.
JO2676B1 (en) 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Substituted diaza-spiro-(4,5)-Decane derivatives and their use as neurokinin antagonists
JP2008510728A (en) 2004-08-19 2008-04-10 バーテックス ファーマシューティカルズ インコーポレイテッド Muscarinic receptor modulators
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
JP2008521825A (en) 2004-11-29 2008-06-26 バーテックス ファーマシューティカルズ インコーポレイテッド Muscarinic receptor modulators
DE602006016244D1 (en) 2005-03-08 2010-09-30 Janssen Pharmaceutica Nv DIAZASPIRO Ä4,4Ü NONANDERIVATES AS NEUROKININ (NK1) ANTAGONISTS
CA2624166A1 (en) * 2005-10-11 2007-04-26 Intermune, Inc. Inhibitors of viral replication
EP1957494A2 (en) * 2005-12-05 2008-08-20 Incyte Corporation Lactam compounds and methods of using the same
CN101374519A (en) 2005-12-22 2009-02-25 弗特克斯药品有限公司 Modulators of muscarinic receptors
NZ570497A (en) 2006-02-22 2011-09-30 Vertex Pharma Spiro condensed 4,4'-quinilino-piperidines derivatives as modulators of muscarinic receptors
JP2009527568A (en) 2006-02-22 2009-07-30 バーテックス ファーマシューティカルズ インコーポレイテッド Modulator of muscarinic receptor
EP2040706A2 (en) 2006-06-29 2009-04-01 Vertex Pharmceuticals Incorporated Modulators of muscarinic receptors
CN101553231A (en) 2006-08-15 2009-10-07 弗特克斯药品有限公司 Modulators of muscarinic receptors
JP2010501561A (en) 2006-08-18 2010-01-21 バーテックス ファーマシューティカルズ インコーポレイテッド Modulator of muscarinic receptor
MX2010003373A (en) 2007-10-03 2010-04-30 Vertex Pharma Modulators of muscarinic receptors.
BR112014012056B1 (en) 2011-11-18 2021-12-14 Heptares Therapeutics Limited MUSCARINE M1 RECEPTOR AGONIST COMPOUNDS, A PHARMACEUTICAL COMPOSITION COMPRISING SUCH COMPOUNDS AND USE THEREOF TO TREAT A COGNITIVE OR PSYCHOTIC DISORDER OR TO TREAT OR REDUCE THE SEVERITY OF ACUTE, CHRONIC, NEUROPATHIC OR INFLAMMATORY PAIN
SI3406609T1 (en) 2014-02-06 2024-10-30 Nxera Pharma Uk Limited Bicyclic aza compounds as muscarinic receptor agonists
GB201404922D0 (en) * 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201504675D0 (en) * 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
TW201922758A (en) 2017-10-24 2019-06-16 美商歐樂根公司 Enamines and diastereo-selective reduction of enamines
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
AU2020256166A1 (en) 2019-04-02 2021-10-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR73633B (en) * 1980-03-10 1984-03-26 Janssen Pharmaceutica Nv
NL8401907A (en) * 1983-06-27 1985-01-16 Sandoz Ag SPIROSUCCINIMIDS AND METHODS FOR PREPARING AND USING THESE SPIROSUCCINIMIDS.
US5574044A (en) * 1994-10-27 1996-11-12 Merck & Co., Inc. Muscarine antagonists

Also Published As

Publication number Publication date
WO1999032489A1 (en) 1999-07-01

Similar Documents

Publication Publication Date Title
AU2307999A (en) Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
AU2206699A (en) Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
AU2111199A (en) Benzenesulfonamides and benzamides as therapeutic agents
AU3185495A (en) Spiro-substituted azacyclic derivatives and their use as therapeutic agents
AU4520697A (en) Use of substituted benzazoles as UV absorbers, new benzazoles and processes for their preparation
AU5842896A (en) Hydrotreating catalyst: composition, preparation, and use thereof
AU3102097A (en) Spiro-piperidine derivatives and their use as therapeutic agents
AU3497295A (en) Compositions and methods for the treatment of body weight disorders, including obesity
AU1709699A (en) 13-oxa prostaglandins for the treatment of glaucoma and ocular hypertension
AU2307899A (en) Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
WO1998039293A3 (en) 13-thia prostaglandins for use in glaucoma therapy
AU4069395A (en) Optically active benzothiepin derivative, its preparation and use
AU8038998A (en) Prophylactic or therapeutic agent for diseases attributable to infection with helicobacters
AU2672795A (en) Benzopyrans and their use as therapeutic agents
AU3268197A (en) Spiro-piperidine derivatives and their use as therapeutic agents
AU2418499A (en) Org-5222 in the treatment of depression
AU3651795A (en) Substituted pyrazolyl-pyrazole derivatives, processes for their preparation and their use as agents with herbicidal action
AU1714599A (en) Treatment of glc1a glaucoma with glucocorticoid antagonists
AU2068295A (en) Skin treatment composition
AU6714996A (en) 2-(fluorenonyl)-carbapenems, compositions and methods of use
AU1249395A (en) Topical treatment of ocular photophobia
AU2306595A (en) Dihydrodibenzo(de,h)isoquinolines derivatives and their use as anti-cancer agents
AU2206499A (en) Muscarinic agents and use thereof to treat glaucoma, myopia, and various other conditions
AU7759698A (en) Hair treatment agents
AU2434297A (en) The use of 5-ht1b/1d agonists to treat ocular pain

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase